A novel peptide-based strategy to enhance GBA1 expression for treating Parkinson’s disease
8.5
来源：
Nature
关键字：
mRNA
发布时间：
2025-11-20 00:08
摘要：
Hirunipin 4, a peptide derived from leeches, has been identified as a novel therapeutic candidate for Parkinson's disease. This study demonstrates that hirunipin 4 enhances GBA1 expression, increases glucocerebrosidase (GCase) activity, and reduces pathological α-synuclein aggregation in neuronal models. Mechanistically, it promotes nuclear translocation of TFEB, a key regulator of lysosomal function, and stabilizes GCase protein levels. The findings suggest that hirunipin 4 could serve as a versatile treatment option for addressing lysosomal dysfunction in neurodegenerative diseases.
原文：
查看原文
价值分投票
评分标准
新闻价值分采用0-10分制，综合考虑新闻的真实性、重要性、时效性、影响力等多个维度。
评分越高，表示该新闻的价值越大，越值得关注。
价值维度分析
domain_focus
1.0分
business_impact
1.0分
scientific_rigor
1.5分
timeliness_innovation
1.5分
investment_perspective
2.5分
market_value_relevance
1.0分
team_institution_background
0.5分
technical_barrier_competition
1.0分
关键证据
Hirunipin 4 significantly enhanced GCase protein levels and enzymatic activity.
The peptide reduced α-synuclein aggregation and improved neuronal viability.
The study provides a novel therapeutic strategy for restoring lysosomal function in Parkinson's disease.
真实性检查
否
AI评分总结
Hirunipin 4, a peptide derived from leeches, has been identified as a novel therapeutic candidate for Parkinson's disease. This study demonstrates that hirunipin 4 enhances GBA1 expression, increases glucocerebrosidase (GCase) activity, and reduces pathological α-synuclein aggregation in neuronal models. Mechanistically, it promotes nuclear translocation of TFEB, a key regulator of lysosomal function, and stabilizes GCase protein levels. The findings suggest that hirunipin 4 could serve as a versatile treatment option for addressing lysosomal dysfunction in neurodegenerative diseases.